GENTRECAD

"GENOME-WIDE CHARACTERIZATION OF TRANSCRIPTIONAL REGULATORY ELEMENTS, PATHWAYS AND ASSOCIATED GENETIC VARIATIONS INVOLVED IN THE PATHOGENESIS OF CORONARY ARTERY DISEASE"

Coordinatore	KAROLINSKA INSTITUTET    more  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Caroline Cognome: Hamilton Email: send email Telefono: 46 8 517 75 959 Fax: 46 8 33 73 94
Nazionalità Coordinatore	Sweden [SE]
Totale costo	170˙697 €
EC contributo	170˙697 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-2-1-IEF
Funding Scheme	MC-IEF
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-03-01   -   2010-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Caroline Cognome: Hamilton Email: send email Telefono: 46 8 517 75 959 Fax: 46 8 33 73 94	SE (STOCKHOLM)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'GENTRECAD builds on PROCARDIS, a large European integrated project designed to identify susceptibility genes for coronary artery disease (CAD). CAD has a complex multifactorial aetiology including a substantial heritable component. The current challenge addressed by GENTRECAD is to identify and characterise the genes and gene variants that are functionally implicated, as a basis for designing new targeted treatments and diagnostics. Inflammation plays a key role in the development of CAD. GENTRECAD will take a systematic approach to the in vivo identification and characterization of genomic regulatory regions and active binding sites of selected transcription factors that are expressed and control gene expression in inflammatory macrophages and aims at revealing common genetic variation that affects these processes. Expected deliverables include a limited number of key regulatory pathways in macrophages that are implicated in CAD. Secondly, novel bioinformatics tools will be provided for in silico prediction of regulatory elements and pathways. Results from GENTRECAD will be relevant to other common disabling multifactorial inflammatory diseases as well. Through GENTRECAD, the applicant will be trained in state-of-the-art methodologies in genomics, proteomics, applied bioinformatics and clinical genetics. The multidisciplinary nature of the project will develop her collaborative skills, promote in dependence and increase competitiveness.'